INCY - Incyte's vitiligo treatment meets late-stage trial main goal

Incyte (INCY) announces that its late-stage studies, testing its ruxolitinib treatment in adolescent and adult patients (age ?12 years) with autoimmune disease vitiligo, met the main goal.Both the TRuE-V1 and TRuE-V2 studies met the primary endpoint, demonstrating significantly more patients treated with ruxolitinib cream 1.5% twice daily ((BID)) achieved a ?75% improvement from baseline in the facial vitiligo area scoring index ((F-VASI75)) compared to patients treated with a vehicle control at Week 24.The studies also met key secondary endpoints including patient reported outcomes, the company said.Based on the findings, Incyte plans to submit marketing applications for ruxolitinib to the U.S. FDA and the European Medicines Agency ((EMA)) in the second half of 2021.Incyte said that data from both studies will be submitted for publication and presentation at an upcoming scientific meeting in the second half of 2021.Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the

For further details see:

Incyte's vitiligo treatment meets late-stage trial main goal